0
0
0
0
1
2
3
$0
Is Bio-Techne solid or fragile? The Finex Financial Health Scanner reads TECH's real financial statements and scores its debt, liquidity, margins, cash flow and growth, with the Altman Z-score, the Piotroski F-score and the red flags explained in plain words.
| Revenue (FY2026) | $1.2B |
|---|---|
| Net income | $181.9M |
| Operating margin | 20.7% |
| Net margin | 15.0% |
| Cash and investments | $264.7M |
| Total debt | $200.0M |
| Free cash flow | $272.6M |
| Revenue growth (1 year) | -0.4% |
Data: Nasdaq and Yahoo Finance. Educational, not financial advice.